Pacific Biosciences of California, Inc.
PACB- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001299130
In the last 90 days, Pacific Biosciences of California, Inc. insiders filed 0 open-market purchases and 1 sale; 223 institutions reported holding it in 13F filings for Q2 2026, worth $320.8M in total; superinvestors ARK Invest and HHLR Advisors (Hillhouse) hold it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $30.4K in total
- 1
- 13F holdersQ2 2026, −5 vs. previous quarter
- 223
- 13F valueReported value at the end of Q2 2026
- $320.8M
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Superinvestors holding PACB, Q2 2026
2 superinvestors report holding Pacific Biosciences of California, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
ARK Invest
Cathie Wood
0.3%
Pacific Biosciences of California, Inc.'s share of the portfolio
- Shares
- 29,781,416
- Value
- $50.0M
HHLR Advisors (Hillhouse)
Zhang Lei
0.2%
Pacific Biosciences of California, Inc.'s share of the portfolio
- Shares
- 918,892
- Value
- $1.54M
Latest insider trades
Open-market purchases and sales by Pacific Biosciences of California, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 (view filing)8:17 PM ET | Aug 17 | 1 day | Van Oene MarkSee Remarks | SSale | −26.9K | $1.13 | −$30.4K | −1.0%2.71M after | |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Gibson James R IISee Remarks | SSale | −88.2K | $1.37 | −$120.8K | −6.6%1.25M after | |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Henry Christian OSee Remarks | SSale | −12.5K | $1.51 | −$18.9K | −0.3%3.58M after | |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Van Oene MarkSee Remarks | SSale | −6.50K | $1.51 | −$9.82K | −0.3%2.24M after | |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Farmer MicheleSee Remarks | SSale | −2.98K | $1.51 | −$4.50K | −1.0%305.9K after | |
| Feb 19, 2026 (view filing) | Feb 17-18 | 2 days | Van Oene MarkSee Remarks | SSale | −184.9K | $1.59 | −$294.9K | −9.6%1.74M after | 2 lots |
| Feb 19, 2026 (view filing) | Feb 17-18 | 2 days | Henry Christian OSee Remarks | SSale | −472.7K | $1.59 | −$753.9K | −15.0%2.67M after | 2 lots |
| Feb 19, 2026 (view filing) | Feb 17-18 | 2 days | Farmer MicheleSee Remarks | SSale | −50.2K | $1.59 | −$80.0K | −18.6%219.1K after | 2 lots |
| Aug 20, 2025 (view filing) | Aug 18 | 2 days | Van Oene MarkSee Remarks | SSale | −26.8K | $1.31 | −$35.2K | −1.4%1.92M after | |
| May 21, 2025 (view filing) | May 19 | 2 days | Farmer MicheleSee Remarks | SSale | −5.20K | $1.00 | −$5.20K | −1.9%269.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Pacific Biosciences of California, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 32,339,550 | $54.3M | 0.00% | +7,072,121+28.0% | Added |
| ARK Investment Management LLCSuperinvestorARK Invest | 29,781,416 | $50.0M | 0.32% | −6,491,872−17.9% | Reduced |
| Softbank Group Corp | 20,451,570 | $34.4M | 0.19% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 13,397,934 | $22.5M | 0.00% | +620,485+4.9% | Added |
| Geode Capital Management, LLC | 7,606,518 | $12.8M | 0.00% | +631,252+9.0% | Added |
| Sumitomo Mitsui Trust Holdings, Inc. | 6,009,715 | $10.1M | 0.01% | −1,028,272−14.6% | Reduced |
| Nikko Asset Management Americas, Inc. | 6,009,715 | $10.0M | 0.13% | −1,028,272−14.6% | Reduced |
| State Street Corp | 5,961,175 | $10.0M | 0.00% | −160,541−2.6% | Reduced |
| Point72 Asset Management, L.P. | 4,787,300 | $8.04M | 0.01% | +4,501,600+1,575.6% | Added |
| Two Sigma Investments, LP | 4,242,599 | $7.13M | 0.01% | +732,986+20.9% | Added |